Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 6/20 | 0.32 |
| ▸ | F7 | P08709 | 6/20 | 0.32 |
| ▸ | F3 | P13726 | 6/20 | 0.32 |
| ▸ | F10 | P00742 | 4/20 | 0.32 |
| ▸ | F11 | P03951 | 3/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | FLT3 | P36888 | 2/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266896 | 0.88 | F7 (0.33) | JAK2JAK1TYK2JAK3F7 | |
| SCHEMBL463802 | 0.82 | GHSR (0.38) | JAK2JAK1TYK2CCNA2CDK2 | |
| SCHEMBL10258468 | 0.78 | PLK4 (0.43) | — | |
| SCHEMBL414903 | 0.76 | MCL1 (0.30) | — | |
| SCHEMBL463794 | 0.72 | — | — | |
| SCHEMBL463786 | 0.72 | MCL1 (0.37) | JAK2JAK1TYK2JAK3KLK1 | |
| SCHEMBL414407 | 0.71 | CCNA2 (0.31) | CCNA2CDK2FLT3CCNA1 | |
| SCHEMBL15338773 | 0.71 | — | — | |
| SCHEMBL463787 | 0.69 | JAK2 (0.34) | JAK2CCNA2CDK2FLT3CCNA1 | |
| SCHEMBL463851 | 0.69 | PLK4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | JAK2 2835/4885JAK1 2671/4885TYK2 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.